Charles Schwab Investment Management Inc Enanta Pharmaceuticals Inc Transaction History

Charles Schwab Investment Management Inc

  • $515 Billion
  • Q3 2024

A detailed history of Charles Schwab Investment Management Inc transactions in Enanta Pharmaceuticals Inc stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 162,398 shares of ENTA stock, worth $1.77 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
162,398
Previous 164,047 1.01%
Holding current value
$1.77 Million
Previous $2.13 Million 20.83%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024
SELL
$10.05 - $16.54 $16,572 - $27,274
-1,649 Reduced 1.01%
162,398 $1.68 Million
Q2 2024

Aug 12, 2024
BUY
$11.43 - $17.02 $34,827 - $51,859
3,047 Added 1.89%
164,047 $2.13 Million
Q1 2024

May 08, 2024
BUY
$10.08 - $17.46 $137,783 - $238,660
13,669 Added 9.28%
161,000 $2.81 Million
Q4 2023

Feb 06, 2024
SELL
$8.18 - $10.78 $76,000 - $100,156
-9,291 Reduced 5.93%
147,331 $1.39 Million
Q3 2023

Nov 08, 2023
BUY
$11.09 - $22.13 $55,061 - $109,875
4,965 Added 3.27%
156,622 $1.75 Million
Q2 2023

Aug 09, 2023
BUY
$20.68 - $39.85 $64,087 - $123,495
3,099 Added 2.09%
151,657 $3.25 Million
Q1 2023

May 11, 2023
BUY
$38.82 - $54.59 $103,571 - $145,646
2,668 Added 1.83%
148,558 $6.01 Million
Q4 2022

Feb 13, 2023
BUY
$40.77 - $53.73 $154,232 - $203,260
3,783 Added 2.66%
145,890 $6.79 Million
Q3 2022

Nov 14, 2022
BUY
$48.29 - $71.27 $380,332 - $561,322
7,876 Added 5.87%
142,107 $7.37 Million
Q2 2022

Aug 15, 2022
SELL
$38.13 - $76.93 $72,256 - $145,782
-1,895 Reduced 1.39%
134,231 $6.35 Million
Q1 2022

May 13, 2022
BUY
$56.06 - $74.11 $384,739 - $508,616
6,863 Added 5.31%
136,126 $9.69 Million
Q4 2021

Feb 11, 2022
BUY
$60.19 - $97.37 $91,308 - $147,710
1,517 Added 1.19%
129,263 $9.67 Million
Q3 2021

Nov 16, 2021
BUY
$41.02 - $58.65 $41,635 - $59,529
1,015 Added 0.8%
127,746 $7.26 Million
Q2 2021

Aug 16, 2021
BUY
$43.76 - $53.11 $91,502 - $111,053
2,091 Added 1.68%
126,731 $5.58 Million
Q1 2021

May 17, 2021
BUY
$41.69 - $54.95 $162,924 - $214,744
3,908 Added 3.24%
124,640 $6.15 Million
Q4 2020

Feb 16, 2021
BUY
$41.16 - $47.47 $115,330 - $133,010
2,802 Added 2.38%
120,732 $5.08 Million
Q3 2020

Nov 13, 2020
BUY
$43.36 - $53.53 $133,288 - $164,551
3,074 Added 2.68%
117,930 $5.4 Million
Q2 2020

Aug 14, 2020
BUY
$46.37 - $57.58 $339,242 - $421,255
7,316 Added 6.8%
114,856 $5.77 Million
Q1 2020

May 15, 2020
SELL
$40.22 - $62.0 $59,485 - $91,698
-1,479 Reduced 1.36%
107,540 $5.53 Million
Q4 2019

Feb 07, 2020
BUY
$57.95 - $66.61 $3,013 - $3,463
52 Added 0.05%
109,019 $6.74 Million
Q3 2019

Nov 08, 2019
BUY
$60.08 - $88.17 $169,786 - $249,168
2,826 Added 2.66%
108,967 $6.55 Million
Q2 2019

Aug 09, 2019
BUY
$81.3 - $97.35 $402,435 - $481,882
4,950 Added 4.89%
106,141 $8.96 Million
Q1 2019

May 14, 2019
BUY
$69.08 - $105.66 $263,471 - $402,987
3,814 Added 3.92%
101,191 $9.67 Million
Q4 2018

Feb 14, 2019
SELL
$65.41 - $84.65 $469,774 - $607,956
-7,182 Reduced 6.87%
97,377 $6.9 Million
Q3 2018

Nov 13, 2018
BUY
$85.46 - $126.37 $874,255 - $1.29 Million
10,230 Added 10.85%
104,559 $8.94 Million
Q2 2018

Aug 08, 2018
BUY
$81.85 - $120.51 $232,044 - $341,645
2,835 Added 3.1%
94,329 $10.9 Million
Q1 2018

May 07, 2018
SELL
$57.91 - $92.15 $334,603 - $532,442
-5,778 Reduced 5.94%
91,494 $7.4 Million
Q4 2017

Jan 17, 2018
BUY
$45.65 - $59.37 $1.86 Million - $2.43 Million
40,853 Added 72.41%
97,272 $5.71 Million
Q3 2017

Nov 13, 2017
BUY
$37.91 - $46.8 $2.14 Million - $2.64 Million
56,419
56,419 $2.64 Million

Others Institutions Holding ENTA

# of Institutions
102
Shares Held
21.1M
Call Options Held
10.4K
Put Options Held
2.3K
View Full List

About ENANTA PHARMACEUTICALS INC

ENTA Quotes by TradingView
  • Ticker ENTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,724,900
  • Market Cap $225M
  • Description
  • Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...
More about ENTA
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email